Literature DB >> 16139891

Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.

Brian Gurbaxani1, Linh L Dela Cruz, Koteswara Chintalacharuvu, Sherie L Morrison.   

Abstract

In this study we analyzed mouse FcRn binding to different recombinant chimeric antibodies with human constant regions. This system has the advantage that in vivo half-life in animals expressing the receptor can be directly correlated with receptor binding kinetics. The goal was to determine which FcRn binding parameters, if any, correlate with the serum half-life of antibodies. We used a BIAcore surface plasmon resonance (SPR) device to study kinetic properties at different pHs and concentrations. The data were analyzed using a new model, the dual bivalent analyte model (DBVA), which postulates that there are two types of FcRn bound to the chip, one low affinity and one high affinity. In addition, it takes into consideration the possibility that the ligand, immunoglobulin G (IgG), can exist as both monomer and as higher molecular forms. While some antibodies bind to FcRn with different kinetics, including antibodies that differ only by containing the kappa or lambda light chain--a result which itself is unexpected--we cannot identify a single FcRn binding parameter that directly correlates with Ab half-life. Importantly, we demonstrate that some IgGs with higher affinity for FcRn do not have extended in vivo half-lives.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16139891     DOI: 10.1016/j.molimm.2005.07.032

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  40 in total

1.  Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.

Authors:  Dhaval K Shah; Alison M Betts
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-12-06       Impact factor: 2.745

2.  Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates.

Authors:  Mauro Acchione; Hyewon Kwon; Claudia M Jochheim; William M Atkins
Journal:  MAbs       Date:  2012-04-26       Impact factor: 5.857

3.  Pharmacokinetic properties of IgG and various Fc fusion proteins in mice.

Authors:  Felix Unverdorben; Fabian Richter; Meike Hutt; Oliver Seifert; Pauline Malinge; Nicolas Fischer; Roland E Kontermann
Journal:  MAbs       Date:  2016       Impact factor: 5.857

4.  pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.

Authors:  M Jack Borrok; Yanli Wu; Nurten Beyaz; Xiang-Qing Yu; Vaheh Oganesyan; William F Dall'Acqua; Ping Tsui
Journal:  J Biol Chem       Date:  2014-12-23       Impact factor: 5.157

Review 5.  How the controller is controlled - neonatal Fc receptor expression and immunoglobulin G homeostasis.

Authors:  Shuo-Wang Qiao; Wayne I Lencer; Richard S Blumberg
Journal:  Immunology       Date:  2006-11-28       Impact factor: 7.397

6.  Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges.

Authors:  Yulia Vugmeyster; Xin Xu; Frank-Peter Theil; Leslie A Khawli; Michael W Leach
Journal:  World J Biol Chem       Date:  2012-04-26

7.  Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.

Authors:  Tilman Schlothauer; Petra Rueger; Jan Olaf Stracke; Hubert Hertenberger; Felix Fingas; Lothar Kling; Thomas Emrich; Georg Drabner; Stefan Seeber; Johannes Auer; Stefan Koch; Apollon Papadimitriou
Journal:  MAbs       Date:  2013-05-29       Impact factor: 5.857

Review 8.  Targeting FcRn for the modulation of antibody dynamics.

Authors:  E Sally Ward; Siva Charan Devanaboyina; Raimund J Ober
Journal:  Mol Immunol       Date:  2015-03-09       Impact factor: 4.407

9.  Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding.

Authors:  Jan Terje Andersen; Muluneh Bekele Daba; Gøril Berntzen; Terje E Michaelsen; Inger Sandlie
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

10.  Enhanced antibody half-life improves in vivo activity.

Authors:  Jonathan Zalevsky; Aaron K Chamberlain; Holly M Horton; Sher Karki; Irene W L Leung; Thomas J Sproule; Greg A Lazar; Derry C Roopenian; John R Desjarlais
Journal:  Nat Biotechnol       Date:  2010-01-17       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.